How AI and a Global Pandemic led to a $175M Investment: Ardis Kadiu’s Element451 Story
From Legislation to Implementation: Understanding Section 1202 Changes — Troutman Pepper Locke Podcast
No Password Required: From Heavy Metal to the Front Lines of Cyber Innovation
12 O’Clock High: Navigating Life’s Challenges: A Journey from Military Service to Mental Health Advocacy with Nick Padlo
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 247: Reimagining Cell Therapy for Solid Tumors with Ming-Wei Chen and Fangheng Zhou of RephImmune
Regulatory Ramblings: Episode 75 - Rethinking Hong Kong’s Startup Ecosystem and Its Legal Foundations with Syed Musheer Ahmed, Joshua Chu, and David Cameron
Money-Saving Licensing Tips for Startups
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 242: Business Planning in Healthcare & Life Sciences with Jennifer McEwen of Maynard Nexsen
From Banks to FinTech: The Evolution of Small Business Lending — The Consumer Finance Podcast
How Startups Can Comply With Ever-Changing Privacy Laws
The Future of Supply Chains: Chris Andrassy on Using AI to Predict & Prevent Disruptions
How IP Can Fuel Your Startup's Growth
Strategies for Startups at Foundation
A Guide to SEP: Standard Essential Patents for Tech Startups
Innovation in Compliance: Visionary Leadership with Jackson Calame
The Entrepreneur's Journey with Kass and Mike Lazerow
AGG Talks: Women in Tech Law Podcast - Episode 6: Navigating the Legal Landscape of Venture Capital: Key Considerations for Startups
Creating Impact Through Innovation: Brandon Kashani on Leading Mission-Driven Startups
A una acción de retener talento
AGG Talks: Cross-Border Business Podcast - Episode 25: Venture Capital Trends and Fundraising Strategies for Foreign Startups Expanding to the U.S.
Ming-Wei Chen and Fanheng Zhou, the scientists behind RephImmune, join hosts Lynnsey and Matthew to discuss how their biotech startup is developing a next-generation cell therapy platform designed to overcome the limitations...more
This week, hosts Matthew and Heather welcome back James Chappell, President and CEO of SCbio, to discuss the organization’s new program, SCbioDrive, an accelerator program for emerging life sciences companies. The group...more
Wilson Sonsini’s inaugural Biotech Summit will address topics of critical importance to Biotech and Biopharmaceutical companies, including early and late-stage venture financing, partnering strategies, current and future AI...more
This week we welcome back our previous guest, Laura Gunter, President of the NC Life Sciences Organization, formally known as NCbio. We discuss the 2023 highlights of the life sciences industry in North Carolina, the dynamic...more
The slowdown in funding for the life sciences sector over the second half of 2022 has been pronounced. Carta, a firm that tracks startup investments, found that biotech seed funding, which hit quarterly peaks of roughly $400...more
As biotech markets begin to show signs of life, how should company leaders and investors prepare for what’s next? Biotech executives, investment bankers and partners from Deloitte’s life sciences practice and Fenwick’s...more
The annual J.P. Morgan Healthcare Conference (JPM), Biotech Showcase, and ancillary meetings are back, live and in-person, in January 2023, providing a unique opportunity to make connections among life sciences and health...more
Wilson Sonsini’s 2020 Technology and Life Sciences IPO Report presents analysis and data related to the pricing of 123 initial public offerings completed by U.S.-based technology and life sciences companies between January 1...more
Early-stage and small to midsize private and public companies in the life sciences sector began 2020 on a high note. Funding, particularly in the biotechnology sector, was pouring into the industry. Even several months into...more
Perhaps nowhere do technology and real estate intersect more deeply than in the life sciences industry, where sophisticated technologies are integral to tenants’ operations. The life sciences industry, which was experiencing...more
In our 2018 year-end review of life sciences and tech IPOs, we noted that life sciences offerings totaled 67 raising an average of $133 million while there were 45 technology deals raising an average of more than $380...more
The business of animal health has traditionally been dominated by the animal health divisions of big pharma companies. But with Pfizer’s 2013 spin-off of its animal health business, now known as Zoetis, the sector has been...more
As a pioneer in DNA synthesis with several patents to her name, Dr. Emily Leproust could have enjoyed a distinguished career without ever leaving the lab. Instead she founded (and just took public) a company that promises to...more